Global Atherosclerosis Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Atherosclerosis Therapeutics Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Atherosclerosis is a disease in which the inside of an artery narrows due to the build up of plaque.
Due to the COVID-19 pandemic, the global Atherosclerosis Therapeutics market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Small Molecules accounting for % of the Atherosclerosis Therapeutics global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as the first line of treatment for decreasing LDL levels in the body, it exhibits secondary effects, such as hepatic enzyme elevation or muscular pain in some patients. Moreover, statins do not decrease the risk of cardiovascular diseases completely and is not recommended for patients having diabetes. This has encouraged researchers to focus on the evaluation of new drug targets, including triglyceride-rich particle metabolism regulators, proteins involved in glycoprotein recognition and clearance, and inflammatory pathways that affect efferocytosis. For instance, new proatherosclerotic pathways, such as lipoprotein A (LPA) and PCSK9 can significantly minimize the risk of atherosclerosis. PCSK9 inhibitors exhibit high therapeutic efficacy in reducing atherogenesis and do not increase the incidence of type 2 diabetes. Although more clinical trials are required for their use among atherosclerosis patients, continuous R&D in this field will positively impact the growth of the atherosclerosis therapeutics market.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Atherosclerosis Therapeutics market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Atherosclerosis Therapeutics market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Atherosclerosis Therapeutics market. Readers of the report can become informed about current and future trends of the global Atherosclerosis Therapeutics market and how they will impact market growth during the forecast period.
AstraZeneca Plc
Bayer AG
Merck & Co. Inc.
Novartis AG
Sanofi
Segment by Type
Small Molecules
Biologics
Hospital
Clinic
Research Institute
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Atherosclerosis Therapeutics in global and regional level.
Chapter 3Detailed analysis of Atherosclerosis Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Atherosclerosis Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Atherosclerosis Therapeutics market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Small Molecules accounting for % of the Atherosclerosis Therapeutics global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Hospital segment is altered to an % CAGR throughout this forecast period.
The identification of new drug targets for atherosclerosis will be one of the critical atherosclerosis therapeutics market trends driving the growth of the market. Although statins are regarded as the first line of treatment for decreasing LDL levels in the body, it exhibits secondary effects, such as hepatic enzyme elevation or muscular pain in some patients. Moreover, statins do not decrease the risk of cardiovascular diseases completely and is not recommended for patients having diabetes. This has encouraged researchers to focus on the evaluation of new drug targets, including triglyceride-rich particle metabolism regulators, proteins involved in glycoprotein recognition and clearance, and inflammatory pathways that affect efferocytosis. For instance, new proatherosclerotic pathways, such as lipoprotein A (LPA) and PCSK9 can significantly minimize the risk of atherosclerosis. PCSK9 inhibitors exhibit high therapeutic efficacy in reducing atherogenesis and do not increase the incidence of type 2 diabetes. Although more clinical trials are required for their use among atherosclerosis patients, continuous R&D in this field will positively impact the growth of the atherosclerosis therapeutics market.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Atherosclerosis Therapeutics market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Atherosclerosis Therapeutics market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Atherosclerosis Therapeutics market. Readers of the report can become informed about current and future trends of the global Atherosclerosis Therapeutics market and how they will impact market growth during the forecast period.
By Company
AstraZeneca Plc
Bayer AG
Merck & Co. Inc.
Novartis AG
Sanofi
Segment by Type
Small Molecules
Biologics
Segment by Application
Hospital
Clinic
Research Institute
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Atherosclerosis Therapeutics in global and regional level.
Chapter 3Detailed analysis of Atherosclerosis Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Atherosclerosis Therapeutics revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices